

CURRICULUM VITAE
DANIEL A. NIKCEVICH, MD, PhD

BUSINESS ADDRESS:

The Duluth Clinic, Ltd.¹
400 East Third Street
Duluth, MN 55805

PRIMARY PRACTICE SITE:

The Duluth Clinic, Ltd.¹
dba Essentia Health Duluth Clinic
420 East First Street
Duluth, MN 55805

PRESENT POSITIONS:

2012- President and Chief Medical Officer, Essentia Health East Region,
Duluth, MN
2010- Member, Essentia Medical Group-Duluth²
2010- Chair, Department of Oncology, Essentia Health Duluth Clinic, Duluth,
MN
2007- Section Chief, Section of Hematology and Oncology, Essentia Health
Duluth, Duluth, MN
2005 - Medical Director, Essentia Health Cancer Center, Duluth, MN
2002- Staff Physician, Section of Hematology and Oncology, Essentia Health
Duluth Clinic, Duluth, MN

AFFILIATIONS:

The Duluth Clinic, Ltd., dba

- Essentia Health Hayward Clinic
- Essentia Health Virginia Clinic
- Essentia Health Hibbing Clinic

Riverwood Healthcare Center³
University Medical Center-Mesabi³

MEDICAL STAFF PRIVILEGES:

SMDC Medical Center, dba

- Essentia Health Duluth

St. Mary's Medical Center, dba

- Essentia Health St. Mary's Medical Center

¹ This facility is a wholly owned subsidiary of Essentia Health. See attached "Essentia Health Facilities". The Essentia Institute of Rural Health, a wholly owned corporation of Essentia Health, is assigned oversight of research and education for Essentia Health.

² The Essentia Medical Group was formed to provide a common practice environment for all physicians and credentialed providers within Essentia Health.

³ It is noted that this facility is not an Essentia Health facility; therefore, research will not be conducted at this facility under the Essentia Health FWA.

DANIEL A. NIKCEVICH, MD, PhD

PAGE 2:

PAST POSITIONS:

2005-2011 Chief of Hematology and Oncology, Section of Hematology and Oncology, Essentia Health St. Mary's Medical Center, Duluth, MN
2004-2011 Section Chief, Section of Hematology and Oncology, Essentia Health Cancer Center and Essentia Health St. Mary's Medical Center, Duluth, MN
1984-1986 Biological Research Technician, Edward J. Hines, Jr. Veterans Administration Hospital, Hines, IL
1983-1984 Marine Biologist, Channel Islands Research Program, Marine Science Institute, University of California, Santa Barbara, CA

CERTIFICATION:

2003-2013 American Board of Medical Specialties (ABMS), Subspecialty: Medical Oncology
2003-2013 ABMS, Subspecialty: Hematology

LICENSURE:

Minnesota
Wisconsin

EDUCATION:

1988-1995 Rush Medical College, PhD Immunology, Chicago, IL
1986-1995 Rush Medical College, MD, Chicago, IL
1979-1983 Carleton College, BA Biology, Northfield, MN

POSTGRADUATE TRAINING:

2002-2002 Duke University Medical Center, Department of Internal Medicine, Hematology/Oncology Fellowship, Durham, NC
1999-2000 Duke University Medical Center, Department of Internal Medicine, Chief Resident, Durham, NC
1998-1999 Duke University Medical Center, Department of Internal Medicine Hematology/Oncology Fellowship, Durham, NC
1998 Duke University Medical Center, Department of Internal Medicine, Assistant Chief Resident, Durham, NC
1996-1998 Duke University Medical Center, Department of Internal Medicine, Resident, Durham, NC
1995-1996 Duke University Medical Center, Department of Internal Medicine, Intern, Durham, NC

ACADEMIC APPOINTMENTS:

2002- University of Minnesota School of Medicine, Department of Family Medicine, Adjunct Assistant Professor, Duluth, MN

COMMITTEES/ADMINISTRATIVE RESPONSIBILITIES:

2009-2012	Duluth Clinic Foundation Board, Duluth, MN, Chair
2009-2011	North Central Cancer Treatment Group (NCCTG) Membership Committee, Rochester, MN, Chair
2008-2012	Duluth Clinic Board of Directors, Duluth, MN, Member
2008-2009	Duluth Clinic Foundation Board, Duluth, MN, Vice-Chairman
2006-2011	NCCTG Membership Committee, Rochester, MN, Member
2005-	Duluth Clinic Community Clinical Oncology Program, Principal Investigator
2004-2008	Mayo Clinic Cancer Research Consortium Executive Committee, Rochester, MN, Member
2004-2006	SMDC Health System Foundation Board, Duluth, MN, Member
2004-2011	North Central Cancer Treatment Group Executive Committee, Rochester, MN, Member
2004-	NCCTG, Principal Investigator for Duluth Clinic Cancer Center

HONORS/AWARDS:

2007	Physician of the Year, Duluth Clinic, Duluth, MN
2007	Duluth Clinic Foundation Research Award, Duluth, MN
2001	Boehringer-Ingelheim Pharmaceuticals, Inc., Post-Doctoral Fellowship, National Marrow Donation Program and The Marrow Foundation
2000	Greenfield Scholar, Department of Internal Medicine, Duke University Medical Center
1999	Terry and Frances Seelinger Fellow in Cancer Research, Duke Comprehensive Cancer Center
1995	Upjohn Research Achievement Award, Rush Medical College
1993	Sigma Xi Outstanding Medical Student Research Award, Rush Medical College

PROFESSIONAL MEMBERSHIPS AND SOCIETIES:

2002-2010	North Central Cancer Treatment Group
2002-2010	Eastern Cooperative Oncology Group
2002-2010	National Surgical Adjuvant Breast and Bowel Project
2000-2010	American Society for Blood and Marrow Transplantation
1998-2010	American Society of Clinical Oncology
1998-2010	American Society of Hematology
1996-2010	American College of Physicians
1995-2010	Sigma Xi Research Honor Society

FUNDED RESEARCH/GRANTS RECEIVED:

1. Principle Investigator, Community Clinical Oncology Program (CCOP), Duluth Clinic Cancer Center, Duluth, MN 2005-

PUBLICATIONS - JOURNAL ARTICLES:

1. Sinicrope FA, Foster NR, Yoon HH, Smyrk TC, Kim GP, Allegra CJ, et al. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2012;30(4):406-12. Epub 2011/12/29. doi: 10.1200/JCO.2011.39.2563. PubMed PMID: 22203756; PubMed Central PMCID: PMC3269966.
2. Ansell SM, Tang H, Kurtin PJ, Koenig PA, Nowakowski GS, Nikceвич DA, et al. Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma. *Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK*. 2011. Epub 2011/10/22. doi: 10.1038/leu.2011.297. PubMed PMID: 22015775; PubMed Central PMCID: PMC3266999.
3. Micallef IN, Maurer MJ, Wiseman GA, Nikceвич DA, Kurtin PJ, Cannon MW, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. *Blood*. 2011;118(15):4053-61. Epub 2011/06/16. doi: 10.1182/blood-2011-02-336990. PubMed PMID: 21673350; PubMed Central PMCID: PMC3204728.
4. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011;29(20):2787-94. Epub 2011/06/03. doi: 10.1200/JCO.2010.33.3005. PubMed PMID: 21632504; PubMed Central PMCID: PMC3139394.
5. Kottschade LA, Suman VJ, Amatruda T, 3rd, McWilliams RR, Mattar BI, Nikceвич DA, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). *Cancer*. 2011;117(8):1704-10. Epub 2011/04/08. doi: 10.1002/cncr.25659. PubMed PMID: 21472717; PubMed Central PMCID: PMC3116030.
6. Maurer MJ, Micallef IN, Cerhan JR, Katzmann JA, Link BK, Colgan JP, et al. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011;29(12):1620-6. Epub 2011/03/09. doi: 10.1200/JCO.2010.29.4413. PubMed PMID: 21383282; PubMed Central PMCID: PMC3082979.
7. Grothey A, Nikceвич DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2011;29(4):421-7. Epub 2010/12/30. doi: 10.1200/JCO.2010.31.5911. PubMed PMID: 21189381; PubMed Central PMCID: PMC3058288.
8. Rizzieri DA, Storms R, Chen D-F, Long G, Yang Y, Nikceвич DA, Gasparetto C, Horwitz M, Chute J, Sullivan K, Hennig T, Misra D, Apple C, Baker M, Morris A, Green PG, Hasselblad V, and Chao NJ. Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. *Biol Blood Marrow Transplant* 2010 Aug. 16(8):1107-1114. Epub 2010 Feb 24.

9. Jaeckle KA, Ballman KV, Giannini C, Schomberg PJ, Ames MM, Reid JM, McGovern RM, Safgren SL, Galanis E, Uhm JH, Brown PD, Hammack JE, Arusell R, Nikceovich DA, Morton RF, Wender DB, and Buckner JC. Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM. *J Neurooncol* 2010 Aug. 99(1):73-80. Epub 2010 Jan 12.
10. Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NL, Dakhil SR, Mattar BI, Nikceovich DA, Novotny P, Sekulic A, and Loprinzi CL. Does Sunscreen Prevent Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash? Results of a Placebo-Controlled Trial from the North Central Cancer Treatment Group (N05C4). *Oncologist* 2010 Aug 26. Epub 2010 Aug 28.
11. Jatoi A, Ritter HL, Dueck A, Nguyen PL, Nikceovich DA, Luyun RF, Mattar BI, and Loprinzi CL. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). *Lung Cancer* 2010 May. 68(2):234-239. Epub 2009 Aug 12.
12. Chee CE, Jett JR, Bernath AMJ, Foster NR, Nelson GD, Molina J, Nikceovich DA, Steen PD, Flynn PJ, and Rowland KMJ. Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423. *Cancer* 2010 May 15. 116(10):2382-2389. Epub 2010 Mar 9.
13. Dy GK, Hobday TJ, Nelson G, Windschitl HE, O'Connell MJ, Alberts SR, Goldberg RM, Nikceovich DA, and Sargent DJ. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. *Clin Colorectal Cancer* 2009 Apr. 8(2):88-93. Epub 2009 Sep 10.
14. Hines SL, Mincey B, Dentchev T, Sloan JA, Perez EA, Johnson DB, Schaefer PL, Alberts S, Liu H, Kahanic S, Mazurczak MA, Nikceovich DA, and Loprinzi CL. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. *Breast Cancer Res Treat* 2009 Oct. 117(3):603-609. Epub 2009 Feb 12.
15. Santisteban M, Buckner JC, Reid JM, Wu W, Scheithauer BW, Ames MM, Felten SJ, Nikceovich DA, Wiesenfeld M, Jaeckle KA, and Galanis E. Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. *J Neurooncol* 2009 Apr. 92(2):165-175. Epub 2008 Dec 10.
16. Okuno SH, Delaune R, Sloan JA, Foster NR, Maurer MJ, Aubry MC, Rowland KM, Jr., Soori GS, Nikceovich DA, Kardinal CG, Northfelt DW, and Adjei AA. A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021. *Cancer* 2008 Apr 15. 112(8):1772-1779. Epub 2008 Jan 29.
17. Jatoi A, Burch P, Hillman D, Vanyo JM, Dakhil S, Nikceovich D, Rowland K, Morton R, Flynn PJ, Young C, Tan W, North Central Cancer Treatment Group. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. *Urology* 2007 Feb, 69(2):289-94.
18. Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikceovich DA, Warner DO, Novotny P, Kutteh LA, and Wong GY. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind,

- placebo-controlled, crossover trial (N00C3). *Cancer* 2007 Nov 1. 110(9):2110-2118. Epub 2007 Sept 14.
19. Jatoi A, Nguyen PL, Foster N, Sun D, Stella PJ, Campbell M, Tschetter LK, Dakhil SR, Mailliard JA, and Nikceovich DA. Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma. *J Support Oncol* 2007 Jan. 5(1):41-46. Epub 2007 Feb 3.
 20. Steensma DP, Molina R, Sloan JA, Nikceovich DA, Schaefer PL, Rowland KM Jr, Dentchev T, Novotny PJ, Tschetter LK, Alberts SR, Hogan TF, Law A, Loprinzi CL. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. *Journal of Clinical Oncology* 2006 Mar 1, 24(7):1079-89.
 21. Molina JR, Jett JR, Foster N, Lair BS, Carroll TJ, Tazelaar HD, Hillman S, Mailliard JA, Bernath AM Jr, Nikceovich D. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. *American Journal of Clinical Oncology* 2006 Jun, 29(3):246-51.
 22. Jatoi A, Foster N, Wieland B, Murphy B, Nikceovich D, LaPlant B, Palcic MM, Baracos V. The proteolysis-inducing factor: in search of its clinical relevance in patients with metastatic gastric/esophageal cancer. *Diseases of the Esophagus* 2006, 19(4):241-7.
 23. Molina JR, Nikceovich D, Hillman S, Geyer S, Drevyanko T, Jett J, Verdirame J, Tazelaar H, Rowland K, Wos E, Kutteh L., Nair S, Fitch T, Flynn P, Stella P, Adjei AA. A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer. *Cancer Investigation* 2006 Jun-Jul, 24(4):382-9.
 24. Giordano KF, Jatoi A, Stella PJ, Foster N, Tschetter LK, Alberts SR, Dakhil SR, Mailliard JA, Flynn PJ, Nikceovich DA; North Central Cancer Treatment Group. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. *Annals of Oncology* 2006 Apr, 17(4):652-6.
 25. Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikceovich DA, Bearden JD 3rd, Mailliard JA, Tschetter LK, Fitch TR, Kugler JW. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. *Journal of Clinical Oncology* 2006 Mar 20, 24(9):1409-14,. Epub 2006 Feb 27.
 26. Jatoi A, Murphy BR, Foster NR, Nikceovich DA, Alberts SR, Knost JA, Fitch TR, Rowland KM Jr. North Central Cancer Treatment Group. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. *Annals of Oncology* 2006 Jan, 17(1):29-34.
 27. Ingle JN, Suman KM, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin AS, Nikceovich DA, Perez EA. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group (NCCTG) Trial N0032. *Journal of Clinical Oncology* 2006 Mar, 24:1052-56.
 28. Steensma DP, Molina R, Sloan JA, Nikceovich DA, Schaefer PL, Rowland KM, Dentchev T, Tschetter LK, Novotny PJ, Loprinzi CL. A phase III randomized trial of two different dosing schedules of erythropoietin (EPO) in patients with cancer-associated anemia: North Central Cancer Treatment Group (NCCTG) Study N02C2. *Journal of Clinical Oncology* 2006, 24: 1052-56.
 29. Long HJ 3rd, Nelimark RA, Podratz KC, Suman V, Keeney GL, Nikceovich DA, Kugler JW, Rowland, Jr. KM, Kardinal CG and Wos EJ. Phase III comparison of methotrexate,

- vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium. *Gynecologic Oncology* 2006 Mar, 100(3): 501-5.
30. Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikceovich DA, Rowland KM, Fitch TR, Windschitl HE, Hillman SL, Schild SE, Jett JR, Obasaju C, Adjei AA. North Central Cancer Group. May Clinic. Eli Lilly & Company. Randomized Phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. *Journal of Clinical Oncology* 2005 Sep 1, 23(25): 5929-37.
 31. Neelapu SS, Gause BL, Nikceovich DA, Schuster SJ, Winter J, Gockerman JP, Loughran T Jr, Takeshita K, Inghirami G, McGaughey D, Watson TM, Snow S, Kubovic P, Ferraro M, Jones E, Jaffe ES, Schwartzentruber DJ, Danforth D, Sherry R, Kass E, Van Waes C, Reynolds CW, Kwak LW. Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report. *Clinical Lymphoma* 2005 Jun, 6(1): 61-4.
 32. Patel, MO, Nikceovich, DA. The value of looking. Multiple myeloma discovered by an unusual finding in Gram-stained spinal fluid. *North Carolina Medical Journal* 2002 May-June, 63:129-30.
 33. McGaughey DS, Nikceovich DA, Long GD, Vredenburgh JJ, Rizzieri D, Smith CA, Broadwater G, Loftis JS, McDonald C, Morris AK, Folz RJ, Chao NJ. Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation. *Biology of Blood & Marrow Transplantation* 2001, 7(5):274-8.
 34. Nikceovich DA, Abramson MA. Image of the Month. Choledochal cyst. *Gastroenterology* 1998 Feb, 114(2):238, 423.
 35. Nikceovich DA, Finnegan A, Chong AS-F, Williams JW, Bremer EG. Inhibition of IL-2 stimulated protein tyrosine kinase activity by leflunomide. *Agents and Actions* 1995, 41:C279-C282.
 36. Nikceovich DA, Duffie GP, Young MR, Ellis NK, Kaufman GE, Wepsic HT. Stimulation of suppressor cells in the bone marrow and spleens of high dose cyclophosphamide-treated C57B1/6 mice. *Cellular Immunology* 1987 Oct 15, 109(2):349-59.
 37. Ellis NK, Young MR, Nikceovich DA, Newby M, Plioplys R, Wepsic HT. Stimulation of prostaglandin dependent macrophage suppressor cells by the subcutaneous injection of polyunsaturated fatty acids. *Cellular Immunology* 1986 Oct 15, 102(2):251-60.
 38. Nikceovich DA, Young MR, Ellis NK, Newby M, Wepsic HT. Stimulation of hematopoiesis in untreated and cyclophosphamide treated mice by the inhibition of prostaglandin synthesis. *Journal of Immunopharmacology* 1986, 8(3):299-313.
 39. DeSilva MA, Wepsic HT, Mizushima Y, Nikceovich DA, Larson CH. Modification of in vitro and in vivo BCG cell wall-induced immunosuppression by treatment with chemotherapeutic agents or indomethacin. *Journal of the National Cancer Institute* 1985 Apr, 74(4):917-21.

PUBLICATIONS - Abstracts:

1. Rizzieri DA, Storms R, Nikceovich D, Peterson B, Misra D, Apple C, Baker M, Gasparetto C, Horwitz M, Chute J, Morris A, Chao NJ. Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation. *Blood* 2008; 112: Abstract 342.

2. Nikceovich DA, Grothey A, Sloan JA, Kugler JW, Silberstein PT, Dentchey T, Wender DB, Novotny PJ, Windschitl HE, Loprinzi CL. Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG trial N04C7. *2008 ASCO Annual Meeting*; Abstract 4009. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 4009).
3. Kottschade IA, Suman VJ, Amatruda T, McWilliams RR, Dakhil SR, Nikceovich DA, Morton RF, Fitch TR, Jaslowski AJ, Markovic SN. A phase II trial of carboplatin and ABI-007 in patients with unresectable stage IV melanoma, N057E. *2008 ASCO Annual Meeting*; Abstract 9044.
4. Micallef IN, Maurer MJ, Nikceovich DA, Cannon M, Moore DF, Kurtin P, Witzig TE. A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. *2008 ASCO Annual Meeting*; Abstract 8500.
5. Hobday RJ, Rowland K, Dueck A, Northfelt D, Lingle W, Morton R, Fitch T, Nikceovich D, Perez EA. N0537: A North Central Cancer Treatment Group (NCCTG) phase II trial of VEGF Trap in patients with metastatic breast cancer (MBC) previously treated with an anthracycline and/or a taxane. *ASCO 2008 Breast Cancer Symposium*; Abstract 164.
6. *2008 ASCO Annual Meeting*; Abstract 8066. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 8066).
7. Jett JR, Bernath AM, Foster NR, Molina JR, Nikceovich DA, Steen PD, Flynn PJ, Rowland KM, Fitch TR, Adjei AA. Phase II trial of pemetrexed (P) and carboplatin (C) in previously untreated extensive stage disease small cell lung cancer (ED-SCLC): A NCCTG Study.
8. Roy V, Pckaj BA, Northfelt DW, Allred JB, Liu H, Nikceovich DA, Mattar BI, Perez, EA. N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer. *2008 ASCO Annual Meeting*; Abstract 563. *J Clin Oncol* 26: 2008 (May 20 suppl; abstr 563).
9. Inwards, DJ, Hillman, DW, Fishkin PA, White WL, Morton RF, Dakhil SR, Nikceovich DA, Wender DB, Fitch TR, Kurtin PJ. Phase II Study of Rituximab and Cladribine (2-CDA) in Newly Diagnosed Mantle Cell Lymphoma (MCL) (N0189). *Blood* 2006; 108: Abstract 2746.
10. Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, Michalak JC, Salim M, Nikceovich DA, Dakhil SR, Fitch TR. Salvage chemotherapy with rituximab DHAP (RDHAP) for relapsed non-hodgkin lymphoma (NHL): A phase II trial in the North Central Cancer Treatment Group. *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 7574.
11. Inwards DJ, Hillman DW, Fishkin PA, White WL, Morton RF, Dakhil SR, Nikceovich DA, Wedner DB, Fitch TR, Kurtin PJ. Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL) (N0189). *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 17505.
12. Wong GY, Michalak, JC, Sloan JA, Mailliard JA, Nikceovich DA, Novotny PJ, Warner DO, Kutteh L, Dakhil SR, Loprinzi CL. A Phase III Double Blinded, Placebo Controlled, Randomized Trial of Gabapentin in Patients with Chemotherapy-Induced Peripheral Neuropathy: A North Central Cancer Treatment Group Study. *Journal of Clinical Oncology*, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 8001.

13. Steensma DP, Molina R, Sloan JA, Nikceovich DA, Schaefer PL, Rowland KM, Dentchey T, Tschetter LK, Novotny PJ, Loprinzi CL, North Central Cancer Treatment Group. A Phase III Randomized Trial of Two Different Dosing Schedules of Erythropoietin (EPO) in Patients With Cancer-Associated Anemia: North Central Cancer Treatment Group (NCCTG) Study N02C2. *Journal of Clinical Oncology*, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 8031.
14. Jatoi A, Murphy B, Foster N, Nikceovich D, Alberts S, Kugler J, Fitch T, Luyun RF. Oxaliplatin and Capecitabine in Patients with Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia: A Phase II Study from the North Central Cancer Treatment Group. *Journal of Clinical Oncology*, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 4059.
15. Okuno SH, Delaune R, Sloan J, Aubry M, Foster N, Rowland K, Mailliard J, Nikceovich D, Jett J, Bot B. Gemcitabine and epirubicin in patients with malignant pleural mesothelioma (MPM): A North Central Cancer Treatment Group Phase II Study. *Journal of Clinical Oncology*, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 7264.
16. Schild SE, Stella PJ, Brooks BJ, Mandrekar S, Bonner JA, McGinnis WL, Nikceovich DA, Adjei AA, Jatoi A, Jett JR, Mayo Clinic, Scottsdale, AZ; Michigan Cancer Consortium CCOP, Ann Arbor, MI; Ochsner CCOP, New Orleans, LA; Mayo Clinic, Rochester, MN; University of Alabama at Birmingham, Birmingham, AL; Iowa Oncology Research Association CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN. The Results of combined modality therapy for limited stage small cell lung cancer (LD-SCLC) in the elderly. *Journal of Clinical Oncology*, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 7043.
17. Green PD, Foster S, Nikceovich D, Gimble J, Storms R, Duke University Medical Center, Durham, NC; Artec Science, Inc., Durham, NC. Stromal cells derived from subcutaneous adipose tissue support early lymphoid ontogeny. *Proc Am Soc Clin Oncol* 22: 2003 (abstr 3377).
18. Nikceovich DA, Vredenburgh JJ, Broadwater G, Ross M, Shpall EJ, Jones RB, Marks L, Peters WP, Duke University Medical Center, Durham, NC; University of Virginia. Ten year follow-up after high-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. *Proc Am Soc Clin Oncol* 21:2002 (abstr 1657).

PUBLICATIONS - BOOK CHAPTERS:

1. Nikceovich, D. and Cohen, H. Biologic Connections of Cancer and Aging: Monoclonal Gammopathies. Comprehensive Geriatric Oncology, 2nd edition., 2004. L. Balducci, GH Lyman, and WB Ershler, eds.
2. DeSilva MA, Wepsic HT, Mizushima Y, Janss G, Nikceovich DA. Modification of the induction of BCGw suppressor cells by mitomycin-C. In: A Reif, M Mitchell, eds., *Immunity and Cancer*, New York, Academic Press, 1985.

PRESENTATIONS AND PROFESSIONAL MEETINGS:

1. Nikceovich DA. Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG trial N04C7. Presented at the 2008 Annual ASCO Meeting, 2008.
2. Nikceovich DA, Vredenburgh JJ, Broadwater G, Ross M, Shpall EJ, Jones RB, Marks L, Peters WP, Duke University Medical Center, Duham, NC; University of Virginia. Ten year follow-up after high-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Presented at the 2002 Annual ASCO Meeting, 2002.
3. Nikceovich DA, Finnegan A, Bremer EG. Tyrosine kinases and cytokine receptor function: pharmacological investigations of signal transduction pathways. Presented at the Sigma Xi University Research Week, Rush Medical College, Chicago, IL, 1993.
4. Nikceovich DA, Finnegan A, Bremer EG. Tyrosine kinase activities in the IL-2 and IL-4 receptor function. Presented at the Federation of American Societies for Experimental Biology, Anaheim, CA, 1992.
5. Wepsic HT, Young MR, Nikceovich DA, Ellis NK, Newby M. The induction of bone marrow suppressor cells by tumor, polyunsaturated fats, and chemotherapy treatment. Presented at the 6th International Congress of Immunology, Toronto, Canada, 1986.
6. Nikceovich DA, Ellis NK, Young MR, Wepsic HT. Stimulation of hematopoiesis in mice by the inhibition of prostaglandin synthesis. Presented at the 14th Annual Meeting of the MidWest Autumn Immunology Conference, Chicago, IL, 1985.
7. Ellis NK, Nikceovich DA, Wepsic HT. The stimulation of splenic suppressor cells by the administration of polyunsaturated fatty acids. Presented at the 14th Annual Meeting of the MidWest Autumn Immunology Conference, Chicago, IL, 1985.
8. Wepsic HT, Mizushima Y, DeSilva MA, Nikceovich DA. Comparative studies of tumor and Bacillus Calmette Guerin cell wall (BCGcw) induced suppressor cells in rats. 69th Annual Meeting of the Federation of American Societies for Experimental Biology, Anaheim, CA, 1985.
9. DeSilva MA, Wepsic HT, Mizushima Y, Janss G, Nikceovich DA. Modification of the induction of BCGcw suppressor cells by mitomycin-C. Presented at the Williamsburg Conference on Immunity and Cancer, Williamsburg, VA, 1984.